Furthermore, recent studies have explored the feasibility, safety, and anti-tumor activity of the first-in-human approach of targeting CLDN6 with CAR-T therapy and combining it with a CAR-amplifying vaccine (Mackensen et al., 2023), given the frequent detection of high-level CLDN6 in epithelial OC, endometrial carcinoma, and other solid tumors (Jaeger et al., 2014). The gene discussed is CLDN6; the disease is neoplasm.